NCT05655182 - A Study of BLB-201 RSV Vaccine in Infants and Children | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

December 14, 2026

Study Completion Date

December 23, 2026

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

PIV5-vectored RSV Vaccine (BLB-201) Low Dose

BLB201 10\^6 PFU

BIOLOGICAL

PIV5-vectored RSV Vaccine (BLB-201) High Dose

BLB201 10\^7 PFU

DRUG

Placebo

The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).

Trial Locations (11)

44122

RECRUITING

Velocity Clinical Research, Cleveland, Beachwood

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

67114

RECRUITING

AMR Newton, Newton

68803

RECRUITING

Velocity Clinical Research, Grand Island, Grand Island

70508

RECRUITING

Velocity Clinical Research - Lafayette, Lafayette

77030

RECRUITING

Baylor College of Medicine, Houston

78613

RECRUITING

Velocity Clinical Research, Austin, Cedar Park

83440

RECRUITING

Clinical Research Prime, Rexburg

83642

RECRUITING

Velocity Clinical Research, Boise, Meridian

91942

RECRUITING

Paradigm Clinical Research, La Mesa

95355

RECRUITING

Paradigm Clinical Research - Modesto, Modesto